Artelo Biosciences, Inc.
Artelo Biosciences, Inc. (ARTLW) Stock Overview
Explore Artelo Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
13.1K
P/E Ratio
-0.74
EPS (TTM)
$-1.43
ROE
-0.64%
ARTLW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Artelo Biosciences, Inc. (ARTLW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.74 and a market capitalization of 13.1K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Gregory D. Gorgas
5
505 Lomas Santa Fe, Solana Beach, NV
2019